Anika Therapeutics’ CEO will present at the J.P. Morgan Healthcare Conference on January 16, 2025, and meet investors.
Quiver AI Summary
Anika Therapeutics, Inc. has announced that Dr. Cheryl Blanchard, the company's President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 16, 2025, at 9:45 am PT. The presentation will be available for live streaming and will also be archived for 30 days on the company's website. Additionally, Anika's management will hold one-on-one investor meetings during the event. Anika Therapeutics is focused on joint preservation in early intervention orthopedics, specializing in products that utilize hyaluronic acid and implant solutions to enhance orthopedic care, particularly in managing osteoarthritis pain and regenerative solutions. The company is headquartered near Boston, Massachusetts.
Potential Positives
- Participation in the prestigious 43rd Annual J.P. Morgan Healthcare Conference highlights Anika Therapeutics' credibility and position within the healthcare sector.
- Live webcast of the presentation increases visibility and access for investors and stakeholders, showcasing the company's commitment to transparency.
- One-on-one investor meetings provide an opportunity for direct engagement with management, potentially strengthening investor relations and interest in the company.
Potential Negatives
- None
FAQ
When is Anika Therapeutics presenting at the J.P. Morgan Healthcare Conference?
Anika Therapeutics will present on January 16, 2025, at 9:45 am PT / 12:45 pm ET.
Where can I watch the Anika Therapeutics presentation?
The presentation will be webcast live on the Events and Webcasts page on Anika Therapeutics’ website.
Who is Dr. Cheryl Blanchard?
Dr. Cheryl Blanchard is the President and CEO of Anika Therapeutics.
How can I schedule a meeting with Anika’s management?
To schedule a meeting, contact Anika’s Investor Relations at investorrelations@anika.com.
What does Anika Therapeutics focus on?
Anika Therapeutics focuses on joint preservation and early intervention in orthopedic care, including Osteoarthritis Pain Management.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ANIK Hedge Fund Activity
We have seen 47 institutional investors add shares of $ANIK stock to their portfolio, and 68 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 157,707 shares (+9.8%) to their portfolio in Q3 2024
- RIVERWATER PARTNERS LLC added 86,037 shares (+539.1%) to their portfolio in Q3 2024
- AQR CAPITAL MANAGEMENT LLC removed 76,681 shares (-71.4%) from their portfolio in Q3 2024
- NUVEEN ASSET MANAGEMENT, LLC removed 58,761 shares (-58.7%) from their portfolio in Q3 2024
- MORGAN STANLEY removed 49,011 shares (-9.8%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC removed 47,063 shares (-52.8%) from their portfolio in Q3 2024
- VIRTUS INVESTMENT ADVISERS, INC. removed 45,579 shares (-100.0%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BEDFORD, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) --
Anika Therapeutics, Inc.
(NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the 43
rd
Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET. Management will also participate in one-on-one investor meetings throughout the event.
The presentation will be webcast live on the
Events and Webcasts page
under the Investors section of Anika Therapeutics’ website and will be archived for 30 days following the presentation. For more information about this event or to schedule a one-on-one meeting with Anika’s senior management, please contact Anika’s Investor Relations at
investorrelations@anika.com
.
About Anika
Anika Therapeutics, Inc.
(NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit
www.anika.com
.
ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, INTEGRITY, MONOVISC, ORTHOVISC, TACTOSET, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
